<code id='DB3ED64636'></code><style id='DB3ED64636'></style>
    • <acronym id='DB3ED64636'></acronym>
      <center id='DB3ED64636'><center id='DB3ED64636'><tfoot id='DB3ED64636'></tfoot></center><abbr id='DB3ED64636'><dir id='DB3ED64636'><tfoot id='DB3ED64636'></tfoot><noframes id='DB3ED64636'>

    • <optgroup id='DB3ED64636'><strike id='DB3ED64636'><sup id='DB3ED64636'></sup></strike><code id='DB3ED64636'></code></optgroup>
        1. <b id='DB3ED64636'><label id='DB3ED64636'><select id='DB3ED64636'><dt id='DB3ED64636'><span id='DB3ED64636'></span></dt></select></label></b><u id='DB3ED64636'></u>
          <i id='DB3ED64636'><strike id='DB3ED64636'><tt id='DB3ED64636'><pre id='DB3ED64636'></pre></tt></strike></i>

          Home / fashion / leisure time

          leisure time


          leisure time

          author:explore    Page View:24
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In